Back to Results
First PageMeta Content
Endocrine system / MannKind Corporation / Eli Lilly and Company / Insulin therapy / Peptide hormones / Recombinant proteins / Diabetes management / Insulin / Diabetes mellitus / Medicine / Health / Diabetes


XX-1 CI-1 AFREZZA® Technosphere® Insulin Inhalation System NDA[removed]
Add to Reading List

Open Document

File Size: 1,79 MB

Share Result on Facebook

Company

Regulatory Affairs MannKind Corporation / The Schein Group Inc. / Type / NDA 022472 MannKind Corporation / Statistical Consultant Adaptive Plus LLC / Patricia Frank & Associates / DrPH / /

Event

FDA Phase / /

Facility

Lankenau Institute / /

MedicalCondition

pulmonary function effects / lung cancer / COPD / Pulmonary safety / Type 2 diabetes mellitus / Cough / Favorable hypoglycemia / Cardiovascular Diseases / chronic lung diseases / Asthma / /

MedicalTreatment

Insulin Therapy / /

Organization

Jefferson Medical College / FDA / Lankenau Institute for Medical Research / Johns Hopkins University School of Medicine / Metabolic Drugs Advisory Committee / IND NDA / /

Person

John Bedard / R. Kowey / Annette Stemhagen / James Kaye / Jonathan Smith / /

Position

Director of Epidemiology / PhD Consulting Pharmacologist/Toxicologist President / Professor of Medicine and Clinical Pharmacology / Vice President / Safety / FISPE Sr. Vice President / President / Senior Vice President / FACP Chief / Professor of Medicine / /

Product

MedTone / Gen2 / TI-171 / MedTone® Inhaler / /

SocialTag